Department of Experimental Medical Science, Lund University, Sweden.
Department of Experimental Medical Science, Lund University, Sweden.
Vascul Pharmacol. 2021 Jun;138:106837. doi: 10.1016/j.vph.2021.106837. Epub 2021 Jan 29.
Smooth muscle cells contribute significantly to lipid-laden foam cells in atherosclerotic plaques. However, the underlying mechanisms transforming smooth muscle cells into foam cells are poorly understood. The purpose of this study was to gain insight into the molecular mechanisms regulating smooth muscle foam cell formation.
Using human coronary artery smooth muscle cells we found that the transcriptional co-activator MRTFA promotes lipid accumulation via several mechanisms, including direct transcriptional control of LDL receptor, enhanced fluid-phase pinocytosis and reduced lipid efflux. Inhibition of MRTF activity with CCG1423 and CCG203971 significantly reduced lipid accumulation. Furthermore, we demonstrate enhanced MRTFA expression in vascular remodeling of human vessels.
This study demonstrates a novel role for MRTFA as an important regulator of lipid homeostasis in vascular smooth muscle cells. Thus, MRTFA could potentially be a new therapeutic target for inhibition of vascular lipid accumulation.
平滑肌细胞在动脉粥样硬化斑块中的富含脂质的泡沫细胞中起重要作用。然而,将平滑肌细胞转化为泡沫细胞的潜在机制仍知之甚少。本研究旨在深入了解调节平滑肌泡沫细胞形成的分子机制。
使用人冠状动脉平滑肌细胞,我们发现转录共激活因子 MRTFA 通过多种机制促进脂质积累,包括 LDL 受体的直接转录控制、增强的液相胞吞作用和减少的脂质外排。用 CCG1423 和 CCG203971 抑制 MRTFA 活性可显著减少脂质积累。此外,我们在人类血管的血管重塑中证明了 MRTFA 的表达增强。
本研究证明了 MRTFA 作为血管平滑肌细胞中脂质稳态的重要调节剂的新作用。因此,MRTFA 可能成为抑制血管脂质积累的新的治疗靶点。